Bangwei S. Cao
Beijing, 100050, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 97 publications
Metabolic crosstalk between extracellular matrix, cancer-associated fibroblasts and tumor cells: drivers of tumor progression and therapeutic resistance.
Journal: International immunopharmacology
Published: July 04, 2026
Navigating Immunotherapy Resistance: The Role of Cross-Line Strategies in Cancer Treatment.
Journal: Journal of clinical medicine
Published: February 13, 2026
Inhibitory effect of the multi-target TKI, anlotinib, in 5-FU resistant colorectal cancer HCT-8/15 cells: down regulation of drug resistance-associated protein expression.
Journal: Frontiers in oncology
Published: January 20, 2026
Exploring the Regulatory Effects of Curcumin on CD47-Overexpressing Esophageal Cancer Cells via Network Pharmacology with Preclinical Validation.
Journal: Current medicinal chemistry
Published: July 27, 2025
Burden of colorectal cancer attributable to diet low in milk among middle-aged and elderly population from 1990 to 2021: a population-based study.
Journal: Aging clinical and experimental research
Published: May 05, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Journal: Nature medicine
Published: March 27, 2025
Corrigendum: Exploring the impact of HDL and LMNA gene expression on immunotherapy outcomes in NSCLC: a comprehensive analysis using clinical & gene data.
Journal: Frontiers in oncology
Published: February 11, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.
Journal: Signal transduction and targeted therapy
Published: January 18, 2025
Dipeptidyl peptidase-4 in the tumor microenvironment of the digestive system: Molecular mechanisms and therapeutic targets.
Journal: International journal of cancer
Published: October 01, 2024
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Journal: Nature medicine
Published: September 29, 2024
Exploring the impact of HDL and LMNA gene expression on immunotherapy outcomes in NSCLC: a comprehensive analysis using clinical & gene data.
Journal: Frontiers in oncology
Published: June 14, 2024
Last Updated: 09/26/2026